Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antineoplastics

Antineoplastics Reactions 1680, p41 - 2 Dec 2017 Myelodysplastic syndrome progressed to acute myeloid leukaemia: case report A female child [exact age at the time of reaction onset not stated] who developed myelodysplastic syndrome (MDS), which progressed to acute myeloid leukaemia (AML) following treatment with carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide and melphalan [not all routes and dosages stated; time to reactions onset and outcomes not stated]. The girl was diagnosed with stage 4 MYCN neuroblastoma (NB) at the age of 3 years. She was started on induction chemotherapy with cisplatin 600 mg/m , etoposide 2 2 1050 mg/m , cyclophosphamide 8000 mg/m and doxorubicin 150 mg/m . She also received ifosfamide. Following the induction chemotherapy, she achieved full remission. Subsequently, she was started on myeloablative chemotherapy with carboplatin 1700 mg/m , melphalan 2 2 210 mg/m and etoposide 1352 mg/m along with autologous stem cell transplant. She was started on maintenance therapy with cis-retinoic acid, which she was not able to tolerate. Hence, she was then started on maintenance therapy with oral cyclophosphamide. Her chemotherapy treatment was discontinued. Later, she developed macrocytic anaemia with mean corpuscular volume 106.6fL. During her subsequent follow-up visits, macrocytic anaemia persisted with hemoglobin levels ranged http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antineoplastics

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017

Antineoplastics

Abstract

Reactions 1680, p41 - 2 Dec 2017 Myelodysplastic syndrome progressed to acute myeloid leukaemia: case report A female child [exact age at the time of reaction onset not stated] who developed myelodysplastic syndrome (MDS), which progressed to acute myeloid leukaemia (AML) following treatment with carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide and melphalan [not all routes and dosages stated; time to reactions onset and outcomes not stated]. The girl was diagnosed with stage 4...
Loading next page...
 
/lp/springer_journal/antineoplastics-0yftLC0h9T

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-38972-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p41 - 2 Dec 2017 Myelodysplastic syndrome progressed to acute myeloid leukaemia: case report A female child [exact age at the time of reaction onset not stated] who developed myelodysplastic syndrome (MDS), which progressed to acute myeloid leukaemia (AML) following treatment with carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide and melphalan [not all routes and dosages stated; time to reactions onset and outcomes not stated]. The girl was diagnosed with stage 4 MYCN neuroblastoma (NB) at the age of 3 years. She was started on induction chemotherapy with cisplatin 600 mg/m , etoposide 2 2 1050 mg/m , cyclophosphamide 8000 mg/m and doxorubicin 150 mg/m . She also received ifosfamide. Following the induction chemotherapy, she achieved full remission. Subsequently, she was started on myeloablative chemotherapy with carboplatin 1700 mg/m , melphalan 2 2 210 mg/m and etoposide 1352 mg/m along with autologous stem cell transplant. She was started on maintenance therapy with cis-retinoic acid, which she was not able to tolerate. Hence, she was then started on maintenance therapy with oral cyclophosphamide. Her chemotherapy treatment was discontinued. Later, she developed macrocytic anaemia with mean corpuscular volume 106.6fL. During her subsequent follow-up visits, macrocytic anaemia persisted with hemoglobin levels ranged

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.